Smith & Nephew SNATS (SNN) vs Zimmer Biomet (ZBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zimmer Biomet (ZBH) has outperformed Smith & Nephew SNATS (SNN) over the past year, losing 9.6% versus a loss of 25.0%. Over five years, SNN leads with a -23.8% price change compared with -37.5% for ZBH. Zimmer Biomet is the larger company by market cap ($17.00 billion vs $11.34 billion), about 1.5 times the size.
On valuation, Zimmer Biomet trades at a lower forward P/E (9.8x vs 11.2x for Smith & Nephew SNATS). Smith & Nephew SNATS offers the higher dividend yield (1.46% vs 1.08%). Smith & Nephew SNATS converts more of its revenue into profit, with a net margin of 10.1% versus 8.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNN | ZBH |
|---|---|---|
| Share price | $27.10 | $89.11 |
| Market cap | $11.34B | $17.00B |
| 1-day change | +0.52% | +0.26% |
| YTD return | -17.83% | -1.16% |
| 1-year return | -24.97% | -9.64% |
| 5-year return | -23.82% | -37.45% |
| P/E ratio (TTM) | 18.44 | 21.63 |
| Forward P/E | 11.24 | 9.83 |
| EPS (TTM) | $1.47 | $4.12 |
| Dividend yield | 1.46% | 1.08% |
| Annual dividend | $0.397 | $0.96 |
| Revenue (latest FY) | $6.16B | $8.23B |
| Revenue growth (YoY) | +6.09% | +7.20% |
| Net income (latest FY) | $625.00M | $705.10M |
| Gross margin | 68.01% | 69.71% |
| Operating margin | 12.88% | 13.34% |
| Net margin | 10.14% | 8.57% |
| 52-week high | $37.51 | $106.88 |
| 52-week low | $26.12 | $79.12 |
| Distance from 52-week high | -27.75% | -16.63% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +19.26% | +20.33% |
| Average volume | 1.65M | 2.17M |
| Shares outstanding | 418.52M | 190.74M |
| Employees | 17,000 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBH has outperformed SNN by 15.3 percentage points over the past year.
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
About Zimmer Biomet
ZBH stock →Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
Health Care · Industrial Specialties · 17,000 employees
SNN vs ZBH FAQ
Which is bigger, Smith & Nephew SNATS or Zimmer Biomet?
Zimmer Biomet (ZBH) is larger, with a market capitalization of $17.00B compared with $11.34B for Smith & Nephew SNATS (SNN).
Which stock has performed better over the past year, SNN or ZBH?
ZBH returned -9.64% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, SNN or ZBH?
SNN has the lower trailing P/E at 18.4, versus 21.6 for ZBH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Smith & Nephew SNATS or Zimmer Biomet?
Smith & Nephew SNATS has the higher yield at 1.46%, compared with 1.08% for Zimmer Biomet.
Are Smith & Nephew SNATS and Zimmer Biomet in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.